中文
 
+
Zhejiang Haichang Biotech Co., Ltd.


Company Profile

Zhejiang Haichang Biotech Co., Ltd.

Zhejiang Haichang Biotech Co., Ltd., Haichang Biotech is a global trailblazer committed to pushing the boundaries of biomedical technologies to better human health. With a strong emphasis on independent innovation and a solid global intellectual property right foundation, we drive the discovery and development of cutting-edge drug delivery systems. Our expertise lies in nucleic acid technologies. We actively contribute to the evolution of mRNA vaccine, small nucleic acid drugs, and complex injections.

 

Our broad product pipelines span various fields, encompassing infectious disease prevention, tumor immunotherapy, antitumor therapy, analgesia and more.

 

Headquartered in Hangzhou Biopharma Town, we have a local heart with a global reach. We blend groundbreaking technologies with international market opportunities, while adapting to the fast-paced biotech evolution. Our mission is to improve global health and well-being. Uniting research and development, manufacturing, marketing, and services, we strive towards a healthier, brighter future for all. 

Global Layout

Netherlands

  • WhiteOak Pharmaceutical B.V.

China

United States

  • The WhiteOak Group, Inc.
Culture and Mission
  • Innovate to empower, we forge a brighter future for patients. With an unwavering commitment to improving health worldwide, we redefine treatment landscapes to fulfill clinical needs, safeguarding the well-being and the lives of all.

Development History
From 2013 to 2017
From 2018 to Now
Development history
01
2013-2017
Stage 1: Focusing on 505(b)(2) modified drugs, featuring the research and development of the QTsome nucleic acid formulation platform

● 2013: Company founded

● 2014: R&D team and early laboratory established

● 2016: laboratory for complex formulations established 

● 2017: Pre-A financing completed 

Development history
02
2018-Now
Stage 2: Focusing on development of innovative nucleic acid drugs for the QTsome platform and commercialization of chemical liposome formulations

● 2018: Collaborated with Rexahn HC0301; A-round financing completed 

● 2019: Collaborated with Dr. Reddys Laboratories in the US on HC007 

● 2020: Collaborated with Rexahn; acquisition of WGI company in the US; A+-round financing completed

● 2021: IND for project HC0301 cleared by US FDA ; concurrent application of project HC007 in China and Europe

● 2022: Construction of innovative nucleic acid drug manufacturing center initiated

● 2022: B+-round financing completed

● 2022: IND for project HC0009 cleared by US FDA

● 2023: HC0301 was granted orphan drug destination from US FDA

● 2024: HC0301 was approved by China NMPA for Clinical Trials

Core Team
+86-571-26262022